

1 **TITLE PAGE**

2

3 **Full-length title:**

4 **Implementation of an in-house real-time reverse transcription-PCR assay to detect the**
5 **emerging SARS-CoV-2 N501Y variants**

6

7 **Short title (for the running head): qPCR for SARS-CoV-2 N501Y variants**

8

9 **Author list:** Marielle BEDOTTO¹, Pierre-Edouard FOURNIER^{1,2}, Linda
10 **HOUHAMDI^{1,2}, Philippe COLSON^{1,2}, Didier RAOULT^{1,2}***

11 **Affiliations:** ¹ IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille,
12 France; ² Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD),
13 Assistance Publique - Hôpitaux de Marseille (AP-HM), MEPHI, 27 boulevard Jean Moulin,
14 13005 Marseille, France

15

16 *** Corresponding author:** Didier RAOULT, IHU - Méditerranée Infection, 19-21 boulevard
17 Jean Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 413 732 402; email:
18 didier.raoult@gmail.com

19

20 **Key words (5):** SARS-CoV-2; Covid-19; N501Y variants; qPCR; diagnosis

21 **Word counts:** abstract: 176; text: 497

22 **Figure:** 0; **Table:** 1; **References:** 6.

23

24

ABSTRACT

25

26 The SARS-CoV-2 pandemic has been associated with the emergence of several variants with
27 a mutated spike glycoprotein that are of substantial concern regarding their transmissibility
28 and ability to evade immune responses. This warrants implementing strategies for their
29 detection and surveillance. We have set up an in-house one-step real-time reverse
30 transcription-PCR (qPCR) assay that specifically detects SARS-CoV-2 spike N501Y variants.
31 Our assay was positive for all 6 patients found spike N501Y-positive by genome sequencing.
32 Ten cDNA samples for each of the 10 Marseille variants identified by genome sequencing
33 and three nasopharyngeal samples of a spike N501Y-negative variant (Marseille-4) that
34 predominates locally tested negative. All negative controls among which 5 SARS-CoV-2-
35 negative nasopharyngeal samples tested negative. First use in the setting of diagnosis on 51
36 nasopharyngeal samples from SARS-CoV-2-positive but Marseille-4-negative patients
37 showed positivity in 5 cases further confirmed by sequencing as from spike N501Y variant-
38 infected patients. Thus, our in-house qPCR system was found reliable for the detection of the
39 N501Y substitution and allowed estimating preliminarily that spike N501Y variant prevalence
40 was 4% among SARS-CoV-2 diagnoses since January 2020.

41

42

43

TEXT

44

45 The SARS-CoV-2 pandemic has been associated with the occurrence of several viral
46 variants with a mutated spike glycoprotein (S). Those currently of greatest concern carry
47 N501Y substitution within the spike (S) receptor binding domain (RBD). Indeed, they have
48 become predominant in England (20I/501Y.V1) [1] and were detected in South Africa
49 (20H/501Y.V2) [2] and Brazil [3]. The 20I/501Y.V1 variant has started to spread worldwide
50 including in France [4]. It has been reported as 50-74% more transmissible than preexisting
51 strains, suspected to evade anti-spike antibodies [1], and it caused a reinfection [5]. Its real-
52 time detection is critical to manage patients appropriately, monitor and assess its
53 epidemiological and clinical features, and survey cases of immune escape post-infection or
54 vaccination. An alternative comprehensive detection strategy is warranted considering the
55 very large number of SARS-CoV-2 cases.

56 We have implemented an in-house one-step real-time reverse transcription-PCR
57 (qPCR) assay that specifically detects SARS-CoV-2 N501Y variants by targeting nucleotide
58 position 23,063 within S gene where A>U leads to N501Y. SARS-CoV-2 genomes from the
59 GISAID database with or without N501Y were used to design primers and a hydrolysis probe.
60 The sequences of these latter and the qPCR conditions are shown in Table 1. Our N501Y-
61 specific assay was positive for all 6 patients identified as 20I/501Y.V1-positive by genome
62 sequencing and for all 3 additional contact patients for whom sequences were not obtained
63 due to low viral load (Ct of qPCR diagnosis test= 32.0-34.0) leading to no amplification by
64 two conventional PCR. Ten cDNA samples, one for each of the 10 Marseille variants [6]
65 identified by genome sequencing, and three additional nasopharyngeal (NP) samples of the
66 Marseille-4 variant that predominates locally (\approx two-thirds of diagnoses) tested negative. All
67 negative controls (5 SARS-CoV-2-negative NP samples and 20 RNA extract-free qPCR

68 mixes) tested negative. The first use for diagnosis purpose conducted on 51 NP samples from
69 SARS-CoV-2 positive (Ct= 10.2-30.8) but Marseille-4-negative patients showed positivity for
70 5 samples, which were confirmed by sequencing as from N501Y variant-infected patients.

71 Our in-house qPCR system was found reliable to detect specifically the N501Y
72 substitution and preliminarily allowed estimating 20I/501Y.V1 variant prevalence to 4%
73 among our current SARS-CoV-2 diagnoses since January. This assay showed better
74 sensitivity than conventional PCR and should be able to detect different N501Y variants. A
75 commercialized RT-PCR diagnosis assay (TaqPath RT-QPCR test) allows the indirect
76 identification of the 20I/501Y.V1 variant by detecting its ORF1a and N genes but not its S
77 gene due to a deletion at positions 21,766-21,772 [4]. However this deletion is also present in
78 strains devoid of the N501Y substitution and was reported in 0.6% of recent SARS-CoV-2
79 diagnoses in France [4]. Moreover, it is absent from the South African and Brazilian N501Y
80 variants, which prevents their identification. Finally, our in-house qPCR test can be widely
81 and easily deployed in laboratories as it runs on any open qPCR microplate platform, does not
82 require technical workers' training, and is as cheap as other in-house qPCR assays. Such
83 approach should allow adapting continuously diagnosis strategies for new SARS-CoV-2
84 variants.

85

86

87 **Author contributions**

88 Conceived and designed the study: PC, DR. Contributed materials/analysis tools: MB, PEF,
89 LH, PC. Analyzed the data: all authors. Wrote the paper: PC, DR.

90

91 **Acknowledgments -Funding**

92 This work was supported by the French Government under the “Investments for the Future”
93 program managed by the National Agency for Research (ANR), Méditerranée-Infection 10-
94 IAHU-03 and was also supported by Région Provence Alpes Côte d’Azur and European
95 funding FEDER PRIMMI (Fonds Européen de Développement Régional-Plateformes de
96 Recherche et d’Innovation Mutualisées Méditerranée Infection), FEDER PA 0000320
97 PRIMMI.

98

99 **Conflicts of interest**

100 The authors declare that they have no known competing financial interests or personal
101 relationships that could have appeared to influence the work reported in this paper. Funding
102 sources had no role in the design and conduct of the study; collection, management, analysis,
103 and interpretation of the data; and preparation, review, or approval of the manuscript.

104

105 **Ethics**

106 This study has been approved by the ethics committee of the University Hospital Institute
107 Méditerranée Infection, Marseille, France, with the registration number 2020-029.

108

109 **References**

110 [1] K. Leung, M.H.Shum, G.M.Leung, T.T.Lam, J.T.Wu. Early transmissibility assessment of
111 the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November
112 2020, Euro. Surveill 26 (2021) .

113 [2] H. Tegally, E. Wilkinson, M. Giovanetti, A. Iranzadeh, V. Fonseca, J. Giandhari, et al.
114 Emergence and rapid spread of a new severe acute respiratory syndrome-related
115 coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa.
116 medRxiv preprint (2020) doi: <https://doi.org/10.1101/2020.12.21.20248640>.

- 117 [3] N.R. Faria, I.M. Claro, D. Candido, L.A. Moyses Franco, P.S. Andrade, T.M. Coletti, et
118 al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary
119 findings, *Virological.org* (2021) [https://virological.org/t/genomic-characterisation-of-an-](https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586)
120 [emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586](https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586).
- 121 [4] A. Bal, G. Destras, A. Gaymard, K. Stefic, J. Marlet, S.A. Eymieux, et al. Two-step
122 strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other
123 variants with spike deletion H69-V70, France, August to December 2020, *medRxiv*
124 preprint. doi: <https://doi.org/10.1101/2020.11.10.20228528>.
- 125 [5] D. Harrington, B. Kele, S. Pereira, X. Couto-Parada, A. Riddell, S. Forbes, et al.
126 Confirmed reinfection with SARS-CoV-2 variant VOC-202012/01, *Clin. Infect. Dis.*
127 (2021) ciab014. doi: 10.1093/cid/ciab014. Online ahead of print.
- 128 [6] P. Colson, A. Levasseur, J. Delerce, H. Chaudet, V. Bossi, M. Ben Kheder, et al. Dramatic
129 increase in the SARS-CoV-2 mutation rate and low mortality rate during the second
130 epidemic in summer in Marseille. *IHU preprint* (2020) doi: [https://doi.org/10.35088/68c3-](https://doi.org/10.35088/68c3-ew82)
131 [ew82](https://doi.org/10.35088/68c3-ew82).
- 132
- 133
- 134

135

TABLE

136

137 **Table 1.** Primers, probe and qPCR conditions

Name	Sequence (5'-3')	Positions *
<i>Primers:</i>		
Pri_IHU_N501Y_F1	ATCAGGCCGGTAGCACAC	22,980-22,997
Pri_IHU_N501Y_R1	AAACAGTTGCTGGTGCATGT	23,135-23,116
<i>Probe (6FAM-labelled):</i>		
Pro_IHU_C_GB_1_MBP	<u>CCACTT</u> ATGGTGTGGTTACCAA	23,058-23,080

138

139 * in reference to SARS-CoV-2 genome GenBank Accession no. NC_045512.2 (Wuhan-Hu-1

140 isolate). The nucleotide carrying the mutation is covered by the probe and underlined.

141 The qPCR was performed by adding 5 µL of extracted viral RNA to 15 µL of reaction

142 mixture containing 5 µL of 4X TaqMan Fast Virus 1-Step Master Mix (Thermo Fisher

143 Scientific, Grand Island, NY, USA), 0.5 µL of forward primer (10 pmol/µL), 0.5 µL of

144 reverse primer (10 pmol/µL), 0.4 µL of probe (10 pmol/µL), and 8.6 µL of water. PCR

145 conditions are as follows: reverse transcription at 50°C for 10 min, then a hold at 95°C for 20

146 sec followed by 40 cycles comprising a step at 95°C for 15 sec and a step at 60°C for 60 sec.

147 This qPCR was run on a LC480 thermocycler (Roche Diagnostics, Mannheim, Germany).

148

149